U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06916442) titled 'Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy' on March 31.
Brief Summary: Malignant solid tumors, characterized by their persistently high incidence and mortality rates, pose a significant threat to human health and life, imposing a substantial societal burden. Molecular imaging enables the non-invasive, in vivo visualization of tumorigenesis and progression at the molecular level. Compared to traditional morphology-based imaging techniques, molecular imaging provides more precise information for early tumor diagnosis, treatment efficacy assessment, and clinical disease management. 18F-FDG PET/CT imagi...